TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06522126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: progressive relaxation exercise
Description: One of the techniques employed to mitigate the prevalence of PMS complaints in women during this period is progressive relaxation exercises (PRE). It is one of the most preferred options due to its simplicity, cost-effectiveness, and reliability. Over the course of numerous years of research, progressive relaxation has been validated as an efficacious approach for regulating muscle tension. These exercises are performed to facilitate the distinction between tension and looseness in the body and to enable the individual to relax on her own in daily life. PRE involves the voluntary, systematic tension and relaxation of large muscle groups in the human body. PRE reduces anxiety levels by reducing muscle tension. It also provides the individual with a sense of profound rest, renewal, and rebirth.
Study: NCT05349565

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL PHYSICAL THERAPY
Description: High frequency TENS for 10 mins, 3 days/week Ankle pumps for blood circulation 10 repetitions x1 set, 3 days/week. Heel slides10 repetitions x1 set, 3 days/week. Open chain knee flexion and extension 10 repetitions x1 set, 3 days/week. SLR (straight leg raise) 10 repetitions x1 set, 3 days/week. Calf stretch 10 repetitions x1 set, 3 days/week. Quad set 10 repetitions x1 set, 3 days/week.~Total 6 sessions each consisting of 30-45 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUSCLE ENERGY TECHNIQUE
Description: Experimental group treated by applying Muscle energy technique along conventional physical therapy.~For MET patient is positioned at maximal comfort and lengthening while engaging the barrier and then patient is asked to perform isometric contraction with 6-10 sec hold and then release and lengthen the muscle 4-5 repetition x 1 set, 3days/week Total 6 sessions each consisting of 30-45 minutes
Study: NCT06096571

Intervention type: DRUG
Group type: OTHER
Intervention: Aterixen
Description: A single dose of R or T drug in each of 2 periods of the study in fasted conditions

Intervention type: DRUG
Group type: OTHER
Intervention: Aterixen
Description: A single dose of R or T drug in each of 2 periods of the study in fasted conditions
Study: NCT06361108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YJ001 for Spray Use
Description: Granules for spray use; Preparation of Dosing Solution: Reconstitute with sterile water (50ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YJ001 for Spray Use
Description: Granules for spray use; Preparation of Dosing Solution: Reconstitute with sterile water (50ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of YJ001 for Spray Use
Description: Inactive Ingredient: Sterile water; Preparation of Dosing Solution: 50ml Sterile water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of YJ001 for Spray Use
Description: Inactive Ingredient: Sterile water; Preparation of Dosing Solution: 50ml Sterile water
Study: NCT06186843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based diet
Description: A two week training program will be completed which consists of information, resources and activities that will help participants transition to a plant-based diet. Each day of the program, participants will engage with material that provides information about how a plant-based diet can improve health outcomes, how to cook plant-based meals, what to shop for when eating plant-based, and other information that will help participants become comfortable with this dietary change. In addition, each participant will have a virtual, weekly check-in with one of the investigators. Finally, participants will be encouraged to attend a once monthly group session with all participants.
Study: NCT05765513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA35(L20200708MP07707, Ministry of Health, Mongolia) was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA injectable solution (H20174089)
Description: The clinical effects of gingival discomfort oritching, redness and swelling, and bleeding from the probing were observed and recorded in patients before and after 7 days of treatment.
Study: NCT04767529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFX
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFX
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT05613465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codonopsis
Description: Codonopsis pilosula Nnannf is oral liquid, which has been approved for listing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is packaged in the same package as the drug
Study: NCT06518408

Intervention type: DRUG
Intervention: Cabotegravir Injectable Product
Description: long-acting regimen dosed every 2-months

Intervention type: DRUG
Intervention: Rilpivirine Injectable Product
Description: long-acting regimen dosed every 2-months
Study: NCT06445205

Intervention type: DIAGNOSTIC_TEST
Intervention: Mitra® device with VAMS® (volumetric absorptive microsampling) technology
Description: Capillary blood sample
Study: NCT06139770

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family based therapy- Metacognitive therapy
Description: Family based therapy and Metacognitive therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family based therapy- Metacognitive therapy
Description: Family based therapy and Metacognitive therapy
Study: NCT05417763

Intervention type: DEVICE
Intervention: Randomized physiological measurements by the two systems
Description: To measure physiological indices (FFR, cRR and RFR), either pressure microcatheter or pressure wire enters one patient's body. Whether it is the pressure microcatheter or pressure wire firstly to enter is randomized. After completion of one system's physiological assessment, the other system will follow for its physiological assessment.

Intervention type: DEVICE
Intervention: Randomized physiological measurements by the two systems
Description: To measure physiological indices (FFR, cRR and RFR), either pressure microcatheter or pressure wire enters one patient's body. Whether it is the pressure microcatheter or pressure wire firstly to enter is randomized. After completion of one system's physiological assessment, the other system will follow for its physiological assessment.
Study: NCT04950621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam
Description: Remimazolam will be administered during induction and maintenance for general anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Propofol will be administered during induction and maintenance for general anesthesia.
Study: NCT05418205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Families with FGP support
Description: Non-randomized controlled trial with four points of measurement ( in 18 months)
Study: NCT05252091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: herombopag olamine tablets
Description: The first day of chemotherapy was d1, and the drug was started from d-5, 5 days before chemotherapy, with oral herombopag 5 mg/day for a maximum of 14 days. After chemotherapy, when the thrombocytopenia rises to ≥200×109/L, drug discontinuation can be considered
Study: NCT06248775

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Prehabilitation Intervention Supported with Technology (Fitbit, glucose sensor and app for diet habits)
Description: During the VITAAAL intervention patients use the Diameter app to monitor their physical activities (in connection with a Fitbit), nutrition (using the Diameter app) and glucose levels (in connection with Freestyle Libre 2 sensors). Before the intervention starts, a three-day period of blinded baseline measurements is performed to measure current habits, motivation and possibilities. Then, individual aims for improving vitality are formulated in consultation with the NP diabetes. Afterwards, patients continue measuring their habits unblinded with the Diameter for the following weeks and weekly evaluate their goals with the nurse practitioner to receive new instructions and/or to adapt the goals
Study: NCT06520644

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wii-based interactive training program
Description: include step basic, hula hoop, table tilt, jogging, jumping, single limb extension. Single limb extension

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy program
Description: Facilitation of balance reactions from standing position including; standing on balance board, standing on one leg, weights shifting from standing position and stoops and recover from standing,Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands,Gait training activities including: walking on balance board, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs,Facilitation of protective reaction from standing position by pushing the child in different directions.Facilitation of rising mechanism through changing position e.g.: from lying to standing and from sitting to standing,Strengthening exercises for back and abdominal muscles as well as upper and lower limbs,Jumping in place and jumping a board.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy program
Description: Facilitation of balance reactions from standing position including; standing on balance board, standing on one leg, weights shifting from standing position and stoops and recover from standing,Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands,Gait training activities including: walking on balance board, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs,Facilitation of protective reaction from standing position by pushing the child in different directions.Facilitation of rising mechanism through changing position e.g.: from lying to standing and from sitting to standing,Strengthening exercises for back and abdominal muscles as well as upper and lower limbs,Jumping in place and jumping a board.
Study: NCT04681976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telematic dance program
Description: Telematic dance program~The dance program will consist of 24 sessions distributed twice a week for a total period of 3 months. Each session will include:~A) Warm up: It will consist of analytical and global movements of increasing intensity and stretching exercises. It will also involve body awareness and motor control exercises.~B) Choreography part: the participants must follow and learn the choreographies. Intensity ranges shall vary between low and moderate. (3-4 in Borg's Modified Scale (0-10)).~C) Cool down: It will consist of global movements of decreasing intensity, stretching, breathing, and relaxing exercises.
Study: NCT05862168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: The participants will receive 3 cycles of Tislelizumab, with 21 days each. 200mg of Tislelizumab will be used intravenously on the first day of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel
Description: The participants will receive 3 cycles of Albumin paclitaxel, with 21 days each. 200mg/m\^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: The participants will receive 3 cycles of Cisplatin, with 21 days each. 20mg/m\^2 of Cisplatin will be used intravenously on days 1 through 3 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: The participants will receive 3 cycles of 5-Fluorouracil, with 21 days each. 600mg/m\^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
Study: NCT04354649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 5mg/kg PO daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hydroxychloroquine-matching placebo
Study: NCT05615519

Intervention type: DIAGNOSTIC_TEST
Intervention: A new technology based on 3D reconstruction and deep learning algorithm to achieve an automatic diagnosis of strabismus based on patient-sourced videos of programmatic cover tests.
Description: Digital ruler of strabismus
Study: NCT04845711

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: patients will receive general anesthesia only.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block group
Description: patients will receive general anesthesia and bilateral ultrasound guided erector spinae plane block (20ml Bupivacaine 0.25%)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block group
Description: patients will receive general anesthesia and bilateral ultrasound guided quadratus lumborum block (20 ml Bupivacaine 0.25%)
Study: NCT06453889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multimode thermal therapy
Description: The multimode thermal therapy procedure consists of a sequential rapid freezing, natural thawing, and radio-frequency (RF) heating of the target tumor tissue.
Study: NCT05304533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-224
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-224
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYK-224
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Specified dose on specified days
Study: NCT05130515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 200mg po QD, day1\~21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 10mg po QD, day1\~14, 3 weeks/cycle
Study: NCT04638361

Intervention type: OTHER
Intervention: Questionnaires
Description: To explore the quality of life, two questionnaires will be submitted to the parents and the child. The first one is the pediatric version of the VHI (Voice Handicap Index), which explore, using 23 items, the functional, physical and emotional aspects of the dysphonia. The second one is the PEDI-EAT-10 (Pediatric Voice Handicap Index - Eating Assessment Tool), which explore, through 10 items (ranging from 0 to 4), the risk of aspiration and assess the impact of possible dysphagia on quality of life.
Study: NCT05266170

Intervention type: DEVICE
Intervention: aerobic and anaerobic exercises
Description: \[aerobic\]~1. Aerobic treadmill walking program without EX1~2. Aerobic treadmill walking program with EX1~3. High-intensity interval exercise (HIIT) program with EX1~\[anaerobic\]~1. Fitness exercise program with EX1
Study: NCT05083117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XW001
Description: It is anticipated that inhalation of 1 mg XW001 solution up to 14 days will result in a relatively lower systemic exposure in COVID-19 patients on oxygen therapy compared to that in healthy participants as COVID-19 patients tend to have impaired lung function of diffusive, restrictive, obstructive, or mixed origins.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is anticipated that inhalation of 1 mg Placebo solution up to 14 days will result in a relatively lower systemic exposure in COVID-19 patients on oxygen therapy compared to that in healthy participants as COVID-19 patients tend to have impaired lung function of diffusive, restrictive, obstructive, or mixed origins.
Study: NCT05802121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apple Cider Vinegar
Description: Each patient will be instructed to take 6 enteric slow-release acetate capsules (equivalent of 500 mg/ capsule containing 25 mg acetate x 6 capsules) per day for 3 months~https://www.webbernaturals.com/en-ca/apple-cider-vinegar-500-mg-capsules/

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patient will be instructed to take 6 placebo capsules per day for 3 months
Study: NCT05569070

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Young United Parents! Website Intervention
Description: Participants assigned to Guided YUP! will receive two months of structured use of the YUP! website intervention, which involves weekly review of written and video content, meetings with near-peer mentors, use of the goal tool, interaction with the online community, and receipt of tips and affirmations.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Nutrition Website
Description: Participants assigned to the Nutrition Website will be provided with the link to the MyPlate website, which is maintained by the U.S. Department of Agriculture. At the enrollment session, participants will be given brief instruction during the enrollment session about features available on the website that may be interesting to them and encouraged to engage in any of the website or app features at whatever level they are comfortable with. No further direction will be provided to them after the enrollment session.
Study: NCT05882708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: After randomization, the starting dose of ivabradine, 5mg, is given via the gastrointestinal tract every 12 hours. Heart rate control ranged from 70 to 94 bpm. Ivabradine was maintained until 96 hours after initiation of therapy. Beyond this period, the decision to continue ivabradine is left to the discretion of the treating intensivist. During the drug intervention period, heart rate is assessed before each dose. Ivabradine is tapered or discontinued if the heart rate is lower than the target rate; If the heart rate remains ≥95 bpm after 48 hours, the dose is increased to 7.5mg. If a heart rate of 95 or more bpm recurs after discontinuation during the intervention period, treatment with ivabradine can be resumed. Furthermore, Ivabradine is also discontinued at any time in the presence of severe liver impairment, malignant arrhythmia, cardiac conduction block, allergy, the need to take drugs with potentially harmful effects of ivabradine.
Study: NCT05398913

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rimonabant
Description: Rimonabant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimonabant
Description: Rimonabant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimonabant
Description: Rimonabant
Study: NCT05868122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Naproxen Sodium Fixed Combination
Description: Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT05577117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: drugs are injected with induction of general anesthesia
Study: NCT06370429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercises, randomized pretest-posttest
Description: experimental and control ,a randomized pretest-posttest study to examine
Study: NCT06425692

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Education on basic palliative care via e-learning + webinar to deepen knowledge.
Study: NCT04532606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane is provided when considered necessary.
Study: NCT05454072

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinonasal Microbiota Transfer
Description: Pre-screened donor mucus, up to 15mL, will be transplanted into each diseased sinus via nasal lavage.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Sinonasal Microbiota Transfer
Description: Saline, up to 15mL, will be transplanted into each diseased sinus via nasal lavage.
Study: NCT04769388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed/Carboplatin
Description: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for up to 6 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
Study: NCT06227104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Convection-based Hemodiafiltration
Description: Convection-based Hemodiafiltration with pre substitution fluid
Study: NCT06445114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Low risk pathology with post-op HPV DNA (-): cisplatin-based chemoradiation with 30 Gy in 15 fractions and 3 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, and 15 of radiation.~Low risk pathology with post-op HPV DNA (+): cisplatin-based chemoradiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation.~High risk pathology with post-op HPV DNA (-), excluding patients with both 5 LN+ and ENE+ or pre-op HPV DNA≤12 copies/mL: cisplatin-based radiation with 40 Gy in 20 fractions and 4 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, and 22 of radiation.~High risk pathology with post-op HPV DNA (+) OR pre-op HPV DNA≤12 copies/mL OR both 5 or more LN+ and ENE+: cisplatin-based radiation with 50 Gy in 25 fractions with 5 cycles of weekly cisplatin 40mg/m2 IV on Days 1, 8, 15, 22, and 29 of radiation.